Select advances and upcoming approaches in systemic therapies in MF/SS
| Drug . | Mechanism . | Approvala . | ORRb . | Compartmental effect (ORR)2 . | Notable adverse reaction(s) . |
|---|---|---|---|---|---|
| Brentuximab vedotin7 | Anti-CD30 ADC | R/R CD30+ MF after 1 prior systemic therapy | 65.6% | ≤IIA: 53% IIB: 68% IIA-IIIB: 75% IVA: 100% (2/2)c IVB: 57% | Peripheral sensory and motor neuropathy |
| Mogamulizumab8 | Anti-CCR4 Ab | R/R MF/SS after 1 prior systemic therapy | MF: 21% SS: 37% | Skin: 42% Node: 17% Blood: 68% Viscera: 0%d | Infusion-related reaction, rash (see text for discussion) |
| E777740 | Recombinant IL2-diptheria toxin protein | R/R MF/SS after 1 prior systemic therapy | 36.2% | — | Infusion-related reaction, capillary leak syndrome, visual impairment |
| Lacutamab14-16 | Anti-KIR3DL2 Ab | No | SS: 37.5%e | Skin: 46.4% Node: 19.6% Blood: 48.2% Viscera: NR | Peripheral edema |
| Pembrolizumab17 | Anti–PD-1 therapy | No (NCCN) | 38% | IB: 0% (0/1) IIB: 100% (2/2) IIIA: 100% (2/2) IIIB: 33% (1/3) IVA: 25% (4/16) | Rash/flare, immune-related toxicity |
| Tislelizumab41 | Anti–PD-1 therapy | No | 46% | — | Rash/flare, immune-related toxicity (observed in only 1 patient with SS in study, recovered within 4 days) |
| DR-01 (NCT05475925) | Anti-CD94 Ab targeting cytotoxic TCLs, including MF, PCAETCL, PCGDTCL | No | Ongoing study, with data to be reported | ||
| Drug . | Mechanism . | Approvala . | ORRb . | Compartmental effect (ORR)2 . | Notable adverse reaction(s) . |
|---|---|---|---|---|---|
| Brentuximab vedotin7 | Anti-CD30 ADC | R/R CD30+ MF after 1 prior systemic therapy | 65.6% | ≤IIA: 53% IIB: 68% IIA-IIIB: 75% IVA: 100% (2/2)c IVB: 57% | Peripheral sensory and motor neuropathy |
| Mogamulizumab8 | Anti-CCR4 Ab | R/R MF/SS after 1 prior systemic therapy | MF: 21% SS: 37% | Skin: 42% Node: 17% Blood: 68% Viscera: 0%d | Infusion-related reaction, rash (see text for discussion) |
| E777740 | Recombinant IL2-diptheria toxin protein | R/R MF/SS after 1 prior systemic therapy | 36.2% | — | Infusion-related reaction, capillary leak syndrome, visual impairment |
| Lacutamab14-16 | Anti-KIR3DL2 Ab | No | SS: 37.5%e | Skin: 46.4% Node: 19.6% Blood: 48.2% Viscera: NR | Peripheral edema |
| Pembrolizumab17 | Anti–PD-1 therapy | No (NCCN) | 38% | IB: 0% (0/1) IIB: 100% (2/2) IIIA: 100% (2/2) IIIB: 33% (1/3) IVA: 25% (4/16) | Rash/flare, immune-related toxicity |
| Tislelizumab41 | Anti–PD-1 therapy | No | 46% | — | Rash/flare, immune-related toxicity (observed in only 1 patient with SS in study, recovered within 4 days) |
| DR-01 (NCT05475925) | Anti-CD94 Ab targeting cytotoxic TCLs, including MF, PCAETCL, PCGDTCL | No | Ongoing study, with data to be reported | ||
This column refers to approval status with the United Stated Food and Drug Administration (FDA).
Response rates in MF/SS are highly nuanced and depend on the response criteria used as well as disease stage, type of lesion (ie, patch, plaque, or tumor), and compartment (ie, skin, blood, lymph nodes, or organ). We encourage direct consultation with the referenced publication to review response rates in detail.
Note that B2 blood involvement was not eligible for the ALCANZA trial.7
Note that only 3 patients with visceral disease received mogamulizumab.7
Results in this row show data from lacutamab use in the SS cohort of the TELLOMAK train. (Not shown are results from the MF cohort.)
Ab, antibody; ADC, antibody-drug conjugate; CR, complete response; KIR3DL2, killer cell immunoglobulin-like receptor 3DL2; MF, mycosis fungoides; NCCN, National Comprehensive Cancer Network; NR, not reported; TTNT, time to next treatment.